455 related articles for article (PubMed ID: 20624322)
41. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
42. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
Chen TD; Chang IC; Liu HP; Wu YC; Wang CL; Chen YT; Chen YR; Huang SF
Chang Gung Med J; 2012; 35(4):309-17. PubMed ID: 22913857
[TBL] [Abstract][Full Text] [Related]
43. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
44. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
[TBL] [Abstract][Full Text] [Related]
45. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.
Penzel R; Schirmacher P; Warth A
J Thorac Oncol; 2012 Jul; 7(7):1198-9. PubMed ID: 22706607
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.
Wang Y; Wang S; Xu S; Qu J; Liu B
PLoS One; 2014; 9(10):e110617. PubMed ID: 25360721
[TBL] [Abstract][Full Text] [Related]
47. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
48. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
Ren S; Kuang P; Zheng L; Su C; Li J; Li B; Chen X; Wang Y; KimCurran V; Liu L; Hu Q; Zhang J; Tang L; Zhou C
Cell Biochem Biophys; 2012 Nov; 64(2):155-60. PubMed ID: 22707299
[TBL] [Abstract][Full Text] [Related]
49. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
Mitiushkina NV; Iyevleva AG; Poltoratskiy AN; Ivantsov AO; Togo AV; Polyakov IS; Orlov SV; Matsko DE; Novik VI; Imyanitov EN
Cancer Cytopathol; 2013 Jul; 121(7):370-6. PubMed ID: 23408463
[TBL] [Abstract][Full Text] [Related]
50. Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.
Zhong WZ; Su J; Xu FP; Zhai HR; Zhang XC; Yang XN; Chen ZY; Chen ZH; Li W; Dong S; Zhou Q; Yang JJ; Liu YH; Wu YL
Lung Cancer; 2015 Nov; 90(2):205-11. PubMed ID: 26391021
[TBL] [Abstract][Full Text] [Related]
51. Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.
Zhu YC; Liao XH; Wang WX; Xu CW; Zhuang W; Wei JG; Du KQ
Thorac Cancer; 2018 Feb; 9(2):324-327. PubMed ID: 29251824
[TBL] [Abstract][Full Text] [Related]
52. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.
Robesova B; Bajerova M; Liskova K; Skrickova J; Tomiskova M; Pospisilova S; Mayer J; Dvorakova D
Lung Cancer; 2014 Jul; 85(1):25-30. PubMed ID: 24792336
[TBL] [Abstract][Full Text] [Related]
53. Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique.
Fu S; Wang F; Shao Q; Zhang X; Duan LP; Zhang X; Zhang L; Shao JY
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):245-54. PubMed ID: 25839699
[TBL] [Abstract][Full Text] [Related]
54. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.
Chen X; Zhang J; Hu Q; Li X; Zhou C
Lung Cancer; 2013 Aug; 81(2):308-10. PubMed ID: 23731739
[TBL] [Abstract][Full Text] [Related]
55. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract][Full Text] [Related]
56. Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history.
Furukawa M; Soh J; Yamamoto H; Ichimura K; Shien K; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Toyooka S; Miyoshi S
Acta Med Okayama; 2013; 67(1):19-24. PubMed ID: 23439505
[TBL] [Abstract][Full Text] [Related]
57. [Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].
Zeng Z; Wu Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):880-4. PubMed ID: 22104224
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
59. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
60. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
Murakami S; Yokose T; Saito H; Sakuma Y; Matsukuma S; Hasegawa C; Kondo T; Oshita F; Ito H; Tsuboi M; Nakayama H; Kameda Y; Noda K; Yamada K
Lung Cancer; 2010 Sep; 69(3):361-4. PubMed ID: 20659620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]